Active Stocks
Fri Dec 08 2023 15:59:53
  1. Tata Steel share price
  2. 129.2 -0.62%
  1. HDFC Bank share price
  2. 1,653.1 1.38%
  1. State Bank Of India share price
  2. 614 0.35%
  1. NTPC share price
  2. 285.25 0.42%
  1. ITC share price
  2. 449.15 -1.95%
Business News/ Companies / News/  Lupin, Cipla said to bid for UCB’s $1 billion US generics business
Back Back

Lupin, Cipla said to bid for UCB’s $1 billion US generics business

The Indian companies submitted first-round offers for UCB's Kremers Urban Pharmaceuticals unit in late April

Lupin Ltd is India’s second-largest drug maker by market value. Photo: BloombergPremium
Lupin Ltd is India’s second-largest drug maker by market value. Photo: Bloomberg

Mumbai/London: Lupin Ltd, India’s second-largest drug maker by market value, and Cipla Ltd are among companies that bid for UCB SA’s US generic-drug business, people with knowledge of the matter said.

The Indian companies submitted first-round offers for UCB’s Kremers Urban Pharmaceuticals Inc. unit in late April, the people said, asking not to be identified because the process is private. The business could be valued at about $1 billion, four of the people said.

UCB is trying again to divest the US generics business after a previous $1.5 billion sale to buyout firms agreed in November fell apart. Indian drug makers have been considering acquisitions to better compete with market leader Sun Pharmaceutical Industries Ltd and boost their presence in key markets such as the US.

There’s no assurance suitors such as Lupin and Cipla will proceed to the next round of bidding, and details such as price are subject to change, the people said. Lupin declined to comment in an emailed statement. Cipla said in an emailed statement it’s “constantly in discussions with multiple parties on potential collaboration opportunities" and can’t comment on specific talks.

“We have a broad range of interested parties around the globe," Antje Witte, manager of investor relations at UCB, said by phone. “It’s absolutely too early to comment."

The Brussels-based drug maker is selling Kremers Urban as it focuses on drugs for central nervous system illnesses and immunology. UCB’s previous agreement to divest the generics unit was terminated in December, after the US Food and Drug Administration asked for further studies on its copy of Johnson & Johnson’s Concerta pill for attention deficit hyperactivity disorder.

Sun Pharmaceutical, India’s biggest drugmaker, agreed last year to acquire domestic rival Ranbaxy Laboratories Ltd in an all-stock deal valued at $3.2 billion at the time. Dr. Reddy’s Laboratories Ltd, based in Hyderabad, agreed in April to buy UCB’s brands in India for €118 million ($129 million). Bloomberg

Oliver Staley in London contributed to this story.

Milestone Alert!
Livemint tops charts as the fastest growing news website in the world 🌏 Click here to know more.

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 01 Jun 2015, 04:17 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App